Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 4:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 234 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Metabolism and Excretion Clear all
Completed Phase 1 Interventional

Study to Investigate the Absorption, Distribution, Metabolism and Elimination of [14C]GSK1120212

NCT01387204
View directory record Official record
Conditions
Cancer
Interventions
GSK1120212
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 2, 2026, 4:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Comparison of Low and High Phytosterol Diets With Respect to Cholesterol Metabolism

NCT00860509
View directory record Official record
Conditions
Hypercholesterolemia, Coronary Heart Disease
Interventions
Low Phytosterol and High Phytosterol Diets
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated May 3, 2012 · Synced Oct 2, 2026, 4:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Metabolism, Excretion, and Mass Balance Study of Quemliclustat in Healthy Adult Participants (ARC-24)

NCT07364214
View directory record Official record
Conditions
Healthy Participants
Interventions
Quemliclustat
Drug
Lead sponsor
Arcus Biosciences, Inc.
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 2, 2026, 4:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Absorption, Metabolism, and Excretion of Tucatinib in Healthy Participants

NCT03758339
View directory record Official record
Conditions
Healthy
Interventions
tucatinib
Drug
Lead sponsor
Cascadian Therapeutics Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 29, 2018 · Synced Oct 2, 2026, 4:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Absorption, Distribution, Metabolism, Excretion and Absolute Bioavailability of AG-348 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C]AG-348 and Concomitant Single Intravenous Microdose of [13C6]AG-348

NCT03703505
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AG-348, [13C6]AG-348
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 12, 2018 · Synced Oct 2, 2026, 4:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Metabolism and Excretion of BMS-986369 in Healthy Male Participants

NCT05567510
View directory record Official record
Conditions
Healthy Participants
Interventions
BMS-986369
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 17, 2023 · Synced Oct 2, 2026, 4:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single-Radiolabeled Dose Mass Balance Study To Investigate The Absorption, Metabolism, And Excretion Of [14C] Palbociclib (PD-0332991) In Healthy Male Volunteers

NCT01756768
View directory record Official record
Conditions
Healthy
Interventions
[14C]-PD-0332991
Radiation
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Oct 2, 2026, 4:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Flavanol Absorption, Metabolism and Excretion From Fruit-based Drinks and Other Food Matrixes

NCT03526094
View directory record Official record
Conditions
Healthy
Interventions
Flavanols-capsules, Flavanol-banana blend, Flavanol-high protein drink, Flavanol-berry blend, Flavanol-sports drink, Flavanol-peanut butter toast, Flavanol-oats, Flavanol-yogurt, II- Flavanol drink, II- Flavanol drink + banana blend
Other
Lead sponsor
University of California, Davis
Other
Eligibility
25 Years to 60 Years · Male only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
2
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Oct 10, 2022 · Synced Oct 2, 2026, 4:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Absorption, Metabolism and Excretion (AME) Study of [14C]EDP-305 in Healthy Male Subjects

NCT03748628
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
EDP-305
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 21, 2018 · Synced Oct 2, 2026, 4:06 AM EDT
Active, not recruiting Phase 1 Interventional

Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT

NCT02637934
View directory record Official record
Conditions
Suspected Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Interventions
[18F]FluorThanatrace, PET/CT imaging sessions
Drug · Radiation
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 2, 2026, 4:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

RDEA3170 AME Study

NCT01910506
View directory record Official record
Conditions
Healthy
Interventions
RDEA3170 10 mg
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 9, 2014 · Synced Oct 2, 2026, 4:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Intake-dependent Effect of Cocoa Flavanol Absorption, Metabolism and Excretion in Humans

NCT03201822
View directory record Official record
Conditions
Healthy
Interventions
100 mg of Cocoa Flavanols/70 kg BW, 200 mg of Cocoa Flavanols/70 kg BW, 400 mg of Cocoa Flavanols/70 kg BW, 1000 mg of Cocoa Flavanols/70 kg BW
Other
Lead sponsor
University of California, Davis
Other
Eligibility
25 Years to 40 Years · Male only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Jun 28, 2017 · Synced Oct 2, 2026, 4:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK1265744 Administered as a Single Oral Dose and a Study to Describe the Pharmacokinetics of a Supratherapeutic Dose of GSK1265744 in Healthy Adult Subjects

NCT01848340
View directory record Official record
Conditions
HIV-associated Lipodystrophy Syndrome
Interventions
GSK1265744B (sodium salt) containing 14C-GSK1265744B, 150 mg GSK1265744B, Placebo
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 60 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 4, 2013 · Synced Oct 2, 2026, 4:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Assess Absolute Bioavailability (ABA) of TAK-831 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C]TAK-831 in Male Healthy Participants

NCT04234672
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-831 Oral Tablet, [14C]TAK-831 IV Infusion, [14C]TAK-831 Oral Suspension
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Oct 2, 2026, 4:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study to Determine the Metabolism and Clearance of Baxdrostat

NCT05961384
View directory record Official record
Conditions
Hypertension
Interventions
baxdrostat
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 15, 2023 · Synced Oct 2, 2026, 4:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Study the Absorption, Metabolism, and Excretion of [14C]-Praliciguat in Healthy Male Volunteers

NCT03818295
View directory record Official record
Conditions
Healthy Volunteers
Interventions
[14C]-praliciguat
Drug
Lead sponsor
Cyclerion Therapeutics
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 19, 2019 · Synced Oct 2, 2026, 4:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-KW-6356

NCT04147910
View directory record Official record
Conditions
Healthy Male Subjects
Interventions
KW-6356
Drug
Lead sponsor
Kyowa Kirin, Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Oct 2, 2026, 4:06 AM EDT
Terminated Phase 1 Interventional

A Study of Asacol Absorption, Metabolism and Excretion in Children and Adolescents With Ulcerative Colitis.

NCT00254618
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
mesalamine
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
5 Years to 17 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
22
States / cities
Birmingham, Alabama • Mobile, Alabama • Costa Mesa, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2013 · Synced Oct 2, 2026, 4:06 AM EDT
Completed Phase 2 Interventional

The Effect of Thyroid Hormone on Drug Elimination in Cancer Patients

NCT00080574
View directory record Official record
Conditions
Thyroid Cancer
Interventions
Skin Biopsy
Procedure
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 2, 2026, 4:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Investigating a Single Oral Dose of Fenebrutinib in Healthy Volunteers

NCT03596632
View directory record Official record
Conditions
Healthy Participants
Interventions
Fenebrutinib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 6, 2018 · Synced Oct 2, 2026, 4:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Bioavailability and Pharmacokinetic Study of GDC-0032 in Healthy Volunteers

NCT01967966
View directory record Official record
Conditions
Healthy Volunteer
Interventions
GDC-0032
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 2, 2026, 4:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of (14C) Radiolabeled JNJ-56136379 in Healthy Male Participants

NCT03864601
View directory record Official record
Conditions
Healthy
Interventions
14C-JNJ-56136379
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 2, 2026, 4:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Open-label Trial to Evaluate Mass Balance of Tavapadon at Steady State in Healthy Subjects

NCT04241393
View directory record Official record
Conditions
Healthy Subjects
Interventions
Tavapadon tablet, Tavapadon [14C] suspension
Drug
Lead sponsor
Cerevel Therapeutics, LLC
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Oct 2, 2026, 4:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How [14C]ASP0367 is Processed by the Body in Healthy Men

NCT05217901
View directory record Official record
Conditions
Healthy Volunteers
Interventions
14C-labeled ASP0367
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Oct 2, 2026, 4:06 AM EDT